Fouremm,

Nice find. Here is a link to the pdf of the "Improving stem cell gene therapy for severe Mucopolysaccharidosis II - Research update – October 2016" from Dr. Brian Bigger and Ms. Hélène Gleitz.

It does not disclose the sequence of the peptides used, the receptors (if known) to which they bind, or provide any information that allows for a comparison to Transcendpep. On the surface, I would conclude that this is along the same lines as the Angiopep and Transcendpep strategy of identifying a peptide-mediated approach to cross the blood brain barrier. By using a peptide-mediated approach, all of these technologies are amendable to conjugating the respective peptide to a drug, antibody, enzyme or siRNA. 

The study that is referred to in that Research Update, Brains for Brain abstract, and Gordon Conference abstract is not published yet. So whatever is being presented at these March meetings is very new stuff.

BDAZ